GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Regent Pacific Group Ltd (HKSE:00575) » Definitions » YoY EBITDA Growth

Regent Pacific Group (HKSE:00575) YoY EBITDA Growth : 65.32% (As of Dec. 2024)


View and export this data going back to 1997. Start your Free Trial

What is Regent Pacific Group YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Regent Pacific Group's YoY EBITDA Growth for the quarter that ended in Dec. 2024 was 65.32%.

Regent Pacific Group's EBITDA per Share for the six months ended in Dec. 2024 was HK$-0.06.


Regent Pacific Group YoY EBITDA Growth Historical Data

The historical data trend for Regent Pacific Group's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regent Pacific Group YoY EBITDA Growth Chart

Regent Pacific Group Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 87.62 280.97 -191.85 56.77 45.15

Regent Pacific Group Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 65.26 83.96 -133.78 -1.16 65.32

Regent Pacific Group YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Regent Pacific Group's YoY EBITDA Growth for the fiscal year that ended in Dec. 2024 is calculated as:

YoY EBITDA Growth (A: Dec. 2024 )
=(EBITDA per Share (A: Dec. 2024 )-EBITDA per Share (A: Dec. 2023 ))/ | EBITDA per Share (A: Dec. 2023 ) |
=(-0.147--0.268)/ | -0.268 |
=45.15 %

Regent Pacific Group's YoY EBITDA Growth for the quarter that ended in Dec. 2024 is calculated as:

YoY EBITDA Growth (Q: Dec. 2024 )
=(EBITDA per Share (Q: Dec. 2024 )-EBITDA per Share (Q: Dec. 2023 )) / | EBITDA per Share (Q: Dec. 2023 )) |
=(-0.06--0.173)/ | -0.173 |
=65.32 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Regent Pacific Group YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Regent Pacific Group's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Regent Pacific Group Business Description

Traded in Other Exchanges
Address
5 Queen\'s Road Central, 8th Floor, Henley Building, Hong Kong, HKG
Regent Pacific Group Ltd is an investment holding company that runs through two segments: Biopharma and Corporate Investment. Its Biopharma segment is engaged in the research, development, manufacturing, marketing, and sales of pharmaceutical products, and it also develops artificial intelligence (AI) systems for the field of biological aging clocks. The Corporate Investment segment is engaged in the investment in listed and unlisted corporate entities. The majority of its revenue comes from the Biopharma segment. Its geographical segments are China, Europe, Hong Kong, and Taiwan.
Executives
Mellon James
Galloway Limited
2464344 Ontario Inc. 2101 Beneficial owner
Caravel Ds Fund Ltd. 2101 Beneficial owner

Regent Pacific Group Headlines

No Headlines